Merck Share Price Surges on LIPFENDRA Approval Amid Valuation Concerns

Merck (MRK) is experiencing strong share price momentum after the FDA approved LIPFENDRA, an oral PCSK9 inhibitor for hypercholesterolemia. This approval has built competitive pressure around Merck's key cancer drug franchise, including potential biosimilars to Keytruda.

Merck's recent 30-day and year-to-date share price returns are 17.14% and 41.22%, respectively. The company's one-year total shareholder return of 83.40% suggests sustained optimism around its pipeline and new approvals, despite rising Keytruda-related competition.

Some analysts have raised concerns about Merck's valuation, with the most followed narrative placing fair value at $136.85, compared to the current price of $150.33, which frames the recent rally against a richer pricing backdrop.